Core Viewpoint - Blue Moon is advancing its personal care strategy with the launch of the "Moisturizing Foam Shower Gel," achieving a moisture retention rate of over 98%, signaling its commitment to leading the "future bathing era" [1][2] Group 1: Product Launch and Marketing Strategy - Blue Moon partnered with top influencers for a special promotion of the new "Moisturizing Foam Shower Gel" on Douyin, following previous high-profile marketing events [1] - The new product enhances the existing "Moisturizing" function, improving moisture retention to ≥98%, compared to ≥95% in other variants, addressing skin dryness during autumn and winter [1] - The product line now features a functional matrix of "Refreshing - Cool - Moisturizing," catering to various skin types and seasonal bathing needs [1] Group 2: Brand Positioning and Market Strategy - The series promotion of the Moisturizing variant reflects Blue Moon's determination to deepen its recognition in the personal care sector and establish a new benchmark in the foam shower market with a "function + experience" dual-driven approach [2] - This initiative represents a further implementation of Blue Moon's "future clean technology" strategy, aiming to solidify its competitive advantage supported by technology [2]

Financial Data and Key Metrics Changes - Ashland's Q4 sales were $478 million, down 8% year over year, primarily due to portfolio optimization initiatives, with adjusted EBITDA at $119 million, down 4% year over year [4][10] - Adjusted EBITDA margin expanded to 24.9%, up 110 basis points from last year, marking the most profitable quarter of the year [10] - Adjusted earnings per share was $1.08, down 14% from the prior year, impacted by a higher effective tax rate [10] Business Line Data and Key Metrics Changes - Life Sciences sales were $173 million, down 10% year over year, primarily due to the divestiture of the nutraceuticals business, but adjusted EBITDA was $55 million, representing a 32% margin [12][14] - Personal Care sales were $151 million, down 7% year-over-year, but on a comparable basis, delivered 5% sales growth with strong volume gains [17] - Specialty Additives sales were $131 million, down 9% year-over-year, but adjusted EBITDA was $29 million, consistent with the prior year, achieving the strongest margin of the year at 22.1% [18][20] - Intermediates faced pricing and volume pressure, with sales at $33 million, down 8% year over year, and adjusted EBITDA of $5 million, representing a 15.2% margin [15][16] Market Data and Key Metrics Changes - Life Sciences showed resilience in pharma demand, achieving low single-digit sales growth year over year, while nutrition end markets were softer [12][13] - Personal Care experienced broad-based gains across end markets and regions, particularly in biofunctional actives and microbial protection [17] - Specialty Additives faced challenges in coatings, particularly in China, India, and the Middle East, but other markets improved [6][20] Company Strategy and Development Direction - Ashland's strategic focus includes portfolio optimization and restructuring, with approximately 85% of its portfolio serving consumer-facing end markets [7][8] - The company aims to deliver resilient long-term value through disciplined execution and clear focus on priorities, with a $60 million manufacturing optimization program underway [9][22] - Future growth is expected to come from globalized sales and innovation-driven growth, targeting $20 million and $15 million respectively for fiscal 2026 [25][29] Management's Comments on Operating Environment and Future Outlook - Management highlighted ongoing macroeconomic challenges but noted strong margins and consistent performance in Q4 [4][9] - The company expects full-year sales for fiscal 2026 to be between $1,835 million and $1,905 million, representing organic growth of 1%-5% [27][28] - Management remains cautious about macro factors like interest rates and housing turnover but believes in the potential for share gains and innovation to drive growth [28][29] Other Important Information - The company completed a $30 million restructuring program, realizing $20 million in savings this year, with another $12 million expected in fiscal 2026 [21] - Total liquidity stood at just over $800 million, with net leverage at 2.9 times, improving to mid-twos after a $103 million tax refund [11] Q&A Session Summary Question: What were volumes in Q4, and what are your volume assumptions for next year? - Management noted a nice pickup in volumes in Life Sciences and Personal Care, with mixed results in coatings, particularly in China [32] Question: Can you elaborate on the weakness in the nutrition side of Life Sciences? - The weakness was primarily in North America and Europe, but recent share gains are expected to support a return to growth [36] Question: How much of the $100 million CapEx is growth CapEx? - Approximately $55 million is for stay-in-business, with the remainder allocated to growth projects supporting globalized initiatives [36][38] Question: How is the competitive intensity from Chinese competitors affecting the business? - Competitive intensity remains a key factor, particularly in the coatings segment, with variations depending on the region [57] Question: What is the expected contribution from the innovation pipeline in 2026? - The company targets $15 million in innovation-driven growth for 2026, with a focus on core technologies [52][53]

Group 1 - Kimberly-Clark announced the acquisition of Kenvue for a total price of $48.7 billion, with existing Kimberly-Clark shareholders holding approximately 54% of the new company and Kenvue shareholders holding the remaining 46% [2] - Kenvue shareholders will receive $3.5 in cash and 0.14625 shares of Kimberly-Clark stock for each share, totaling approximately $21.01 per share, which is considered an attractive offer [2] - The acquisition is expected to be completed in the second half of 2026, but there is uncertainty regarding Kenvue's future development as an independent business or under Kimberly-Clark's leadership [2] Group 2 - Kenvue was formed from Johnson & Johnson's consumer health division, officially becoming independent in September 2022, and was listed on the New York Stock Exchange in May 2023 [3] - Kenvue's financial performance has been underwhelming, with net sales of $15.455 billion in 2024, a year-on-year increase of only 0.1%, and a net profit decline of 38% [3] - In the first half of 2025, Kenvue's net sales decreased by 3.98% to $7.58 billion, and adjusted net profit fell by 11.49% to $1.025 billion [3] Group 3 - Kenvue's brands, including Neutrogena and Listerine, primarily target the mid-to-low-end market, which is characterized by intense competition [4] - The management of Kenvue sees hope in the acquisition by Kimberly-Clark, believing it will provide a broader business platform and stronger resources for product innovation and market expansion [5] - Kimberly-Clark, known for brands like Huggies and Scott, operates in over 175 countries, presenting significant advantages in channels and supply chains [5]

Group 1 - Kenvue has entered into an agreement with Kimberly-Clark to be acquired for up to $48.7 billion, marking one of the largest transactions in the consumer goods sector in recent years [1][2] - The combined annual revenue of Kenvue and Kimberly-Clark is projected to reach $32 billion, positioning the new entity as the second-largest health and personal care product seller globally, behind Procter & Gamble [1][2] - The merger will create a new platform with complementary product offerings, including 10 brands that each generate over $1 billion in annual sales [2][3] Group 2 - Post-merger, Kimberly-Clark and Kenvue shareholders are expected to hold approximately 54% and 46% of the combined company, respectively, with the transaction anticipated to close in the second half of 2026, pending shareholder approval [2] - The merger is expected to yield significant benefits, with projected net revenue of approximately $32 billion and adjusted EBITDA of about $7 billion by 2025, along with an estimated $1.9 billion in cost synergies within three years post-transaction [3]

Core Insights - Kenvue has announced an agreement with Kimberly-Clark for a cash and stock acquisition valued at $48.7 billion, marking one of the largest transactions in the consumer goods sector in recent years [3] - The merger is expected to create a new platform with a combined annual revenue of $32 billion, positioning it as the second-largest health and personal care product seller globally, just behind Procter & Gamble [3][4] - Post-merger, Kimberly-Clark and Kenvue shareholders are projected to hold approximately 54% and 46% of the combined company, respectively, with the transaction anticipated to close in the second half of 2026, pending shareholder approval [3] Company Overview - Kimberly-Clark, founded in 1872, operates in about 70 countries and holds leading positions in personal care products, with brands such as Huggies, Kleenex, Cottonelle, and Scott [3] - Kenvue is known for its popular brands including Listerine, Band-Aid, and Tylenol, which has recently faced controversy [4] Financial Projections - The combined company is projected to achieve an annual net income of approximately $32 billion (around 228 billion RMB) by 2025, with adjusted EBITDA expected to be around $7 billion (approximately 49.9 billion RMB) [4] - The merger is anticipated to generate about $1.9 billion (approximately 13.5 billion RMB) in cost synergies within three years post-transaction [4]

Core Viewpoint - Kimberly-Clark Corporation is acquiring Kenvue in a cash and stock transaction valued at approximately $48.7 billion, representing a multiple of 14.3 times Kenvue's last twelve months adjusted EBITDA, or 8.8 times including expected operational synergies of $2.1 billion [2][14]. Group 1: Transaction Details - Kenvue shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark for each Kenvue share, totaling $21.01 per share based on Kimberly-Clark's closing price as of October 31, 2025 [16]. - The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals [16]. - Kimberly-Clark has secured committed financing from JPMorgan Chase and plans to fund the cash portion of the transaction through its balance sheet and proceeds from the sale of its 51% stake in its International Family Care and Professional (IFP) business [16]. Group 2: Strategic Benefits - The merger will create a complementary product portfolio with iconic brands that serve nearly half of the global population at various life stages, enhancing the combined company's exposure to key categories expected to benefit from long-term growth trends [4][8]. - The combined entity will leverage a strong talent pool and a robust business engine driven by strategic partnerships, category-defining growth, leading science and innovation, differentiated digital models, and excellent operational culture [4][10]. Group 3: Financial Outlook - The combined company is projected to generate approximately $32 billion in annual net revenue and about $7 billion in adjusted EBITDA by 2025, indicating strong growth potential [13]. - Kimberly-Clark and Kenvue have identified approximately $1.9 billion in cost synergies and $500 million in revenue synergies, with a portion offset by $300 million in reinvestment [13]. - The transaction is expected to create immediate value for Kenvue shareholders, with a compelling financial outlook for all stakeholders involved [14].

Core Insights - The annualized core inflation rate for Bosnia's service sector from January to September is estimated at 4.33% [1] - The consumer price index for the service sector has an annualized increase of 4.84% [1] Inflation Drivers - The most significant impact on September's monthly inflation came from telephone and fax services, although their price increase was too low to affect the overall core inflation trend for the year [1] - Healthcare service prices and hotel and restaurant service prices are the main contributors to the sustained rise in core inflation from January to September [1] - Personal care services also experienced price increases, which had a notable impact on core inflation due to their high price weight [1]

Core Viewpoint - Runben Co., Ltd. has shown a mixed performance in terms of stock trading and financial results, with significant fluctuations in financing activities and a notable increase in shareholder numbers, indicating potential investor interest and market volatility [1][2]. Financing Activities - On October 30, Runben Co., Ltd. experienced a financing buy-in of 4.78 million yuan, while financing repayments amounted to 10.72 million yuan, resulting in a net financing outflow of 5.94 million yuan [1]. - The total financing balance reached 314 million yuan, accounting for 11.58% of the circulating market value, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - In terms of securities lending, 300 shares were repaid, and 1,600 shares were sold short, with a total short sale value of 42,000 yuan, and the remaining short position stood at 9,100 shares, with a balance of 239,000 yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Runben Co., Ltd. reported a revenue of 1.238 billion yuan, reflecting a year-on-year growth of 19.28%, while the net profit attributable to shareholders was 266 million yuan, showing a modest increase of 1.98% [2]. - The company has distributed a total of 316 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 26,200, a rise of 57.33%, while the average number of circulating shares per shareholder decreased by 36.44% to 3,948 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Guotai Consumption Preferred Stock and the entry of new shareholders such as Southern CSI 1000 ETF and ICBC Consumption Service Mixed A [3].

Core Viewpoint - The health care brand Kotex has launched a public welfare new retail initiative in Shenzhen's subway stations, aiming to address the lack of menstrual care services in public spaces under the guidance of the Healthy China strategy [1][3]. Group 1: Initiative Overview - Kotex has integrated its value proposition "where there are women, there should be sanitary pads" into the renovation of light boxes at key subway stations in Shenzhen, promoting the idea of visible menstrual care through a semi-transparent design [3]. - The "light box vending machines" are located in high-traffic areas such as the Chegongmiao, Bao'an Center, and Gangxia North subway stations, reaching over 2.78 million commuters daily [3]. - The initiative allows women to receive menstrual care products for free once per menstrual cycle (28 days) at each station, effectively addressing the shortcomings of traditional public welfare services [3]. Group 2: Alignment with National Goals - Kotex actively responds to the "National Women's Development Outline (2021-2030)" by aiming to eliminate the blind spots in menstrual services in public places, targeting commuting hubs, school surroundings, and commercial areas [3]. - The brand's mission is to "liberate Chinese women from menstrual constraints," extending its philosophy of "where there are women, there should be sanitary pads" into the public service sector [3]. Group 3: Community Support Initiatives - In May 2025, Kotex supported the Guangdong Province Baiqi Education Foundation's "Carnation Plan," donating over 400,000 sanitary pads to more than 6,000 girls in schools in Liangshan Prefecture, meeting their menstrual product needs for approximately three months [4]. - Since 2020, Kotex has provided necessary menstrual hygiene products to over 25,000 middle school girls in Liangshan, helping to improve menstrual health levels [4]. - The brand aims to expand its menstrual care initiatives to more public spaces in collaboration with the public and partners [4].

Core Viewpoint - Future Origins has successfully completed its Nalo™ large-scale demonstration project, which serves as a zero-deforestation alternative to commonly used C12/C14 fatty alcohols in household and personal care products [3][4]. Group 1: Project Details - The Nalo™ project produced over 10 tons of specification-compliant raw materials at a comprehensive refining facility [3]. - This successful demonstration is a significant step towards the final investment decision (FID) for the first commercial-scale manufacturing plant [4]. Group 2: Company Insights - Future Origins is a joint venture founded by Geno, Kao, Unilever, and L'Oréal, aimed at commercializing and producing surfactant raw materials for household and personal care applications [3]. - CEO John Gugel emphasized that this achievement validates the product quality and the robustness and scalability of their proprietary technology [5]. Group 3: Market Implications - The purified products from this large-scale production will be sent to existing and potential partners for various application tests in the household and personal care sectors [5]. - Kao has recently signed a purchase agreement covering a significant portion of the planned capacity of Future Origins' first manufacturing plant [5].